Cargando…
Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
Ankylosing spondylitis (AS) is a type of spondyloarthropathies, the diagnosis of which is often delayed. The lack of early diagnosis tools often delays the institution of appropriate therapy. This study aimed to investigate the systemic metabolic shifts associated with AS and TNF inhibitors treatmen...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933516/ https://www.ncbi.nlm.nih.gov/pubmed/33679777 http://dx.doi.org/10.3389/fimmu.2021.630791 |
_version_ | 1783660628491108352 |
---|---|
author | Ou, Jiayong Xiao, Min Huang, Yefei Tu, Liudan Chen, Zena Cao, Shuangyan Wei, Qiujing Gu, Jieruo |
author_facet | Ou, Jiayong Xiao, Min Huang, Yefei Tu, Liudan Chen, Zena Cao, Shuangyan Wei, Qiujing Gu, Jieruo |
author_sort | Ou, Jiayong |
collection | PubMed |
description | Ankylosing spondylitis (AS) is a type of spondyloarthropathies, the diagnosis of which is often delayed. The lack of early diagnosis tools often delays the institution of appropriate therapy. This study aimed to investigate the systemic metabolic shifts associated with AS and TNF inhibitors treatment. Additionally, we aimed to define reliable serum biomarkers for the diagnosis. We employed an untargeted technique, ultra-performance liquid chromatography-mass spectroscopy (LC-MS), to analyze the serum metabolome of 32 AS individuals before and after 24-week TNF inhibitors treatment, as well as 40 health controls (HCs). Multivariate and univariate statistical analyses were used to profile the differential metabolites associated with AS and TNF inhibitors. A diagnostic panel was established with the least absolute shrinkage and selection operator (LASSO). The pathway analysis was also conducted. A total of 55 significantly differential metabolites were detected. We generated a diagnostic panel comprising five metabolites (L-glutamate, arachidonic acid, L-phenylalanine, PC (18:1(9Z)/18:1(9Z)), 1-palmitoylglycerol), capable of distinguishing HCs from AS with a high AUC of 0.998, (95%CI: 0.992–1.000). TNF inhibitors treatment could restore the equilibrium of 21 metabolites. The most involved pathways in AS were amino acid biosynthesis, glycolysis, glutaminolysis, fatty acids biosynthesis and choline metabolism. This study characterized the serum metabolomics signatures of AS and TNF inhibitor therapy. We developed a five-metabolites-based panel serving as a diagnostic tool to separate patients from HCs. This serum metabolomics study yielded new knowledge about the AS pathogenesis and the systemic effects of TNF inhibitors. |
format | Online Article Text |
id | pubmed-7933516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79335162021-03-06 Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy Ou, Jiayong Xiao, Min Huang, Yefei Tu, Liudan Chen, Zena Cao, Shuangyan Wei, Qiujing Gu, Jieruo Front Immunol Immunology Ankylosing spondylitis (AS) is a type of spondyloarthropathies, the diagnosis of which is often delayed. The lack of early diagnosis tools often delays the institution of appropriate therapy. This study aimed to investigate the systemic metabolic shifts associated with AS and TNF inhibitors treatment. Additionally, we aimed to define reliable serum biomarkers for the diagnosis. We employed an untargeted technique, ultra-performance liquid chromatography-mass spectroscopy (LC-MS), to analyze the serum metabolome of 32 AS individuals before and after 24-week TNF inhibitors treatment, as well as 40 health controls (HCs). Multivariate and univariate statistical analyses were used to profile the differential metabolites associated with AS and TNF inhibitors. A diagnostic panel was established with the least absolute shrinkage and selection operator (LASSO). The pathway analysis was also conducted. A total of 55 significantly differential metabolites were detected. We generated a diagnostic panel comprising five metabolites (L-glutamate, arachidonic acid, L-phenylalanine, PC (18:1(9Z)/18:1(9Z)), 1-palmitoylglycerol), capable of distinguishing HCs from AS with a high AUC of 0.998, (95%CI: 0.992–1.000). TNF inhibitors treatment could restore the equilibrium of 21 metabolites. The most involved pathways in AS were amino acid biosynthesis, glycolysis, glutaminolysis, fatty acids biosynthesis and choline metabolism. This study characterized the serum metabolomics signatures of AS and TNF inhibitor therapy. We developed a five-metabolites-based panel serving as a diagnostic tool to separate patients from HCs. This serum metabolomics study yielded new knowledge about the AS pathogenesis and the systemic effects of TNF inhibitors. Frontiers Media S.A. 2021-02-19 /pmc/articles/PMC7933516/ /pubmed/33679777 http://dx.doi.org/10.3389/fimmu.2021.630791 Text en Copyright © 2021 Ou, Xiao, Huang, Tu, Chen, Cao, Wei and Gu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ou, Jiayong Xiao, Min Huang, Yefei Tu, Liudan Chen, Zena Cao, Shuangyan Wei, Qiujing Gu, Jieruo Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy |
title | Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy |
title_full | Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy |
title_fullStr | Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy |
title_full_unstemmed | Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy |
title_short | Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy |
title_sort | serum metabolomics signatures associated with ankylosing spondylitis and tnf inhibitor therapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933516/ https://www.ncbi.nlm.nih.gov/pubmed/33679777 http://dx.doi.org/10.3389/fimmu.2021.630791 |
work_keys_str_mv | AT oujiayong serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy AT xiaomin serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy AT huangyefei serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy AT tuliudan serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy AT chenzena serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy AT caoshuangyan serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy AT weiqiujing serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy AT gujieruo serummetabolomicssignaturesassociatedwithankylosingspondylitisandtnfinhibitortherapy |